Michael A Morse

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi Fulfilling the promise of immunotherapy
    Campbell Bunce
    Curr Opin Mol Ther 8:9-10. 2006
  2. ncbi Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
    Michael A Morse
    Department ofMedicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 112:610-8. 2008
  3. ncbi The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori
    Stephen Y Chui
    Duke University Medical Center, Box 2606, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 14:1883-9. 2005
  4. ncbi Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer
    Michael A Morse
    Duke University Medical Center, Durham, NC, USA
    Expert Opin Biol Ther 9:331-9. 2009
  5. ncbi Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:3017-24. 2005
  6. ncbi Recent developments in therapeutic cancer vaccines
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Nat Clin Pract Oncol 2:108-13. 2005
  7. ncbi Virus-based therapies for colon cancer
    Michael A Morse
    Division of Medical Oncology, Duke University Medical Center, Duke South Clinics, Durham, NC 27710, USA
    Expert Opin Biol Ther 5:1627-33. 2005
  8. ncbi Current immunotherapeutic strategies in colon cancer
    Michael Morse
    Department of Medicine, Duke University Medical Center, 401 MSRB, Research Drive, Durham, NC 27710, USA
    Surg Oncol Clin N Am 16:873-900, x. 2007
  9. ncbi Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer
    Michael A Morse
    Duke University Medical Center, Department of Medicine, Durham, NC 27710, USA
    IDrugs 8:974-7. 2005
  10. ncbi Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb
    Michael A Morse
    Duke University Medical Center, Division of Medical Oncology, Red Zone, Duke South Clinics, Durham, NC 27710, USA
    Curr Opin Mol Ther 7:588-97. 2005

Detail Information

Publications101 found, 100 shown here

  1. ncbi Fulfilling the promise of immunotherapy
    Campbell Bunce
    Curr Opin Mol Ther 8:9-10. 2006
  2. ncbi Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines
    Michael A Morse
    Department ofMedicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 112:610-8. 2008
    ....
  3. ncbi The development of therapeutic and preventive vaccines for gastric cancer and Helicobacter pylori
    Stephen Y Chui
    Duke University Medical Center, Box 2606, Durham, NC 27710, USA
    Cancer Epidemiol Biomarkers Prev 14:1883-9. 2005
    ..pylori requires an understanding of the complex interactions that make up mucosal immunity. An effective vaccine strategy against H. pylori has the potential to affect significantly on population health worldwide...
  4. ncbi Countering tumor-induced immunosuppression during immunotherapy for pancreatic cancer
    Michael A Morse
    Duke University Medical Center, Durham, NC, USA
    Expert Opin Biol Ther 9:331-9. 2009
    ..Vaccines for pancreatic cancer have been challenged by a number of factors, especially the immunosuppressive microenvironment within the tumor that allows for escape from immune surveillance...
  5. ncbi Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:3017-24. 2005
    ..To determine the safety and immunologic and clinical efficacy of a dendritic cell vaccine modified to hyperexpress costimulatory molecules and tumor antigen...
  6. ncbi Recent developments in therapeutic cancer vaccines
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Nat Clin Pract Oncol 2:108-13. 2005
    ..We will discuss the current state of development of cancer vaccines and the relevance for future clinical use of these agents to treat and prevent cancers...
  7. ncbi Virus-based therapies for colon cancer
    Michael A Morse
    Division of Medical Oncology, Duke University Medical Center, Duke South Clinics, Durham, NC 27710, USA
    Expert Opin Biol Ther 5:1627-33. 2005
    ..As considerable research has focused on therapy of colon cancer with viral vectors, this review will illustrate the major concepts of viral therapy of cancers with examples from studies targeting colorectal carcinoma...
  8. ncbi Current immunotherapeutic strategies in colon cancer
    Michael Morse
    Department of Medicine, Duke University Medical Center, 401 MSRB, Research Drive, Durham, NC 27710, USA
    Surg Oncol Clin N Am 16:873-900, x. 2007
    ..The immune system is "programmed" to down-regulate immune responses once they have become activated to avoid the development of autoimmune disease...
  9. ncbi Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer
    Michael A Morse
    Duke University Medical Center, Department of Medicine, Durham, NC 27710, USA
    IDrugs 8:974-7. 2005
  10. ncbi Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb
    Michael A Morse
    Duke University Medical Center, Division of Medical Oncology, Red Zone, Duke South Clinics, Durham, NC 27710, USA
    Curr Opin Mol Ther 7:588-97. 2005
    ....
  11. ncbi MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27410, USA
    Clin Cancer Res 17:3408-19. 2011
    ....
  12. ncbi Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Box 3247, Durham, NC 27710, USA
    J Gastrointest Surg 13:74-84. 2009
    ..The objective of this retrospective study was to determine the effect of multiagent chemotherapy on long-term survival after resection of CLM...
  13. ncbi Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo
    Michael A Morse
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Int J Cancer 126:2893-903. 2010
    ..Based on these results, we feel clinical studies using this approach to target HER2-overexpressing breast cancer, including trastuzumab- and lapatinib-resistant tumors is warranted...
  14. ncbi Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer
    Chris R Kelsey
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 69:770-6. 2007
    ..To compare a neoadjuvant regimen of cisplatin/5-fluorouracil (5-FU) and concurrent radiation therapy (RT) with paclitaxel-based regimens and RT in the management of operable esophageal (EC)/gastroesophageal junction (GEJ) cancer...
  15. ncbi Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2
    Michael A Morse
    Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    J Transl Med 5:42. 2007
    ..We proposed to address these concerns by using cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and antibody responses...
  16. ncbi The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients
    Takuya Osada
    Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    Cancer Immunol Immunother 57:1115-24. 2008
    ..These data suggest that DC differentiation is negatively associated with VEGF levels and may be one explanation for impaired anticancer immunity, especially in patients with advanced malignancies...
  17. ncbi Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Am Coll Surg 206:96-106. 2008
    ..The objective of this retrospective study was to determine if addition of bevacizumab to iri/oxal preoperative chemotherapy increases morbidity after hepatic resection...
  18. ncbi A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer
    Nan Soon Wong
    Duke University Medical Center, Durham, NC, USA
    Clin Colorectal Cancer 10:210-6. 2011
    ..This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer...
  19. ncbi Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Ann Surg Oncol 16:1809-19. 2009
    ..However, prospective randomized trials are needed to determine the optimal timing of chemotherapy...
  20. ncbi Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 24:656-62. 2006
    ..We initiated two phase I trials assessing the combination of gefitinib, capecitabine, and radiation in patients with localized pancreatic and rectal cancer...
  21. ncbi Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy
    Chris R Kelsey
    Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 69:1436-41. 2007
    ..To report patterns of disease recurrence after resection of adenocarcinoma of the duodenum and compare outcomes between patients undergoing surgery only vs. surgery with concurrent chemotherapy and radiation therapy (CT-RT)...
  22. ncbi Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 68:472-8. 2007
    ..A Phase I trial was undertaken to evaluate the combination of bevacizumab, capecitabine, oxaliplatin, and radiation therapy in patients with rectal cancer...
  23. ncbi Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma
    John W Nelson
    Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
    Int J Radiat Oncol Biol Phys 73:148-53. 2009
    ..To clarify the role of radiotherapy with chemotherapy, we performed a retrospective analysis of resected patients who had undergone chemoradiotherapy...
  24. ncbi Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis
    Amy C Hobeika
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunother (1997) 28:63-72. 2005
    ..These assays will better define the quantity and quality of protective immune responses to viral disease and offer insight into the requirements for protective anti-cancer immunity...
  25. ncbi A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Invest 24:9-17. 2006
    ..We addressed the safety of oral eniluracil/5-FU combined with radiation therapy and determined the profile of dose-limiting toxicities and recommended Phase II dose (RPTD) in patients with pancreatic and hepatobiliary cancers...
  26. ncbi A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer
    Nan Soon Wong
    Duke University Medical Center, Durham, NC 27710, USA
    Anticancer Res 31:255-61. 2011
    ..This study was designed to determine the efficacy and tolerability of capecitabine, oxaliplatin and bevacizumab in combination with cetuximab as first-line therapy for advanced colorectal cancer...
  27. ncbi Preparation of peptide-loaded dendritic cells for cancer immunotherapy
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Mol Biotechnol 25:95-9. 2003
    ..We describe the scheme that we are currently using to generate peptide-loaded dendritic cells for our clinical trials of cancer immunotherapy...
  28. ncbi Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma
    A Paiman Ghafoori
    Department of Radiation Oncology, Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, North Carolina 27710, USA
    Int J Radiat Oncol Biol Phys 81:654-9. 2011
    ..Extrahepatic cholangiocarcinoma is an uncommon but lethal malignancy. We analyzed the role of definitive chemoradiotherapy for patients with nonmetastatic, locally advanced extrahepatic cholangiocarcinoma treated at a single institution...
  29. ncbi A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 67:1002-7. 2007
    ..The optimal combination of chemotherapeutic agents with RT is undefined. We evaluated a combination of capecitabine, carboplatin, and paclitaxel with RT in a phase I study...
  30. ncbi NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity
    Takuya Osada
    Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    Cancer Immunol Immunother 55:1122-31. 2006
    ..14). Thus, NK responses following DC vaccination may correlate more closely with clinical outcome than do T cell responses. Monitoring of NK response during vaccine studies should be routinely performed...
  31. ncbi Investigation of HIFU-induced anti-tumor immunity in a murine tumor model
    Zhenlin Hu
    Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA
    J Transl Med 5:34. 2007
    ..This response may play a critical role in a HIFU-elicited anti-tumor immune response which can be harnessed for more effective treatment...
  32. ncbi Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience
    Brian G Czito
    Department of Radiation Oncology, Duke University Medical Center, Box 3085, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 62:1030-4. 2005
    ..To better define the role of adjuvant radiation therapy and chemotherapy, a retrospective analysis of the outcome of patients undergoing surgery and adjuvant therapy was undertaken...
  33. ncbi A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors
    Elizabeth Dugan
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Anticancer Res 30:1251-6. 2010
    ..The aim of this study was to determine the maximally tolerated dose, recommended phase II dose and toxicity profile of capecitabine plus imatinib mesylate combination...
  34. ncbi Immunotherapy of surgical malignancies
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina, USA
    Curr Probl Surg 41:15-132. 2004
  35. ncbi Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA
    Michael A Morse
    Department of Medicine, Medical Center, Box 3233, Durham, North Carolina 27710, USA
    Cancer Invest 21:341-9. 2003
    ..We conclude that it is feasible and safe to administer mRNA-loaded DC to patients with advanced malignancies...
  36. ncbi Increasing vaccine potency through exosome antigen targeting
    Zachary C Hartman
    Duke Comprehensive Cancer Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Vaccine 29:9361-7. 2011
    ..This targeting exosome process could also be adapted for the development of more potent vaccines in some viral and parasitic diseases where the classical vaccine approach has demonstrated limitations...
  37. ncbi A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer
    Ivy Altomare
    Duke University Medical Center, Durham, North Carolina, USA
    Oncologist 16:1131-7. 2011
    ..A phase I study of bevacizumab plus everolimus demonstrated that the combination is safe; activity was seen in several patients with refractory mCRC...
  38. ncbi The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Int J Gastrointest Cancer 32:1-6. 2002
    ..DC-based immunotherapy in this setting is safe and feasible and may lead to prolonged survival...
  39. ncbi A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)
    Karen E Bullock
    Duke University Medical Center, Seeley G Mudd Bldg, 10 Bryan Searle Drive, Box 3052, Durham, NC 27710, USA
    Cancer Chemother Pharmacol 67:465-74. 2011
    ..This study evaluated the safety, tolerability, and pharmacokinetics of bevacizumab, everolimus, and erlotinib combination...
  40. ncbi Dendritic cell-based immunotherapy
    Takuya Osada
    Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Int Rev Immunol 25:377-413. 2006
    ..In addition, issues regarding the optimal dose and clinical setting for the application of DC vaccines remain to be resolved, and recent clinical studies have been designed to begin to address these questions...
  41. ncbi An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity
    Zachary C Hartman
    Department of Surgery, Medicine, Division of Medical Oncology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA
    Clin Cancer Res 16:1466-77. 2010
    ..We designed and tested several HER2 vaccines devoid of oncogenic activity to develop a safe vaccine for clinical use...
  42. ncbi Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer
    Rebekah R White
    Department of Surgery, Duke University Medical Center, Box 3118, Durham, North Carolina 27710, USA
    Ann Surg Oncol 12:214-21. 2005
    ..Characterization of the tumor cells that survive neoadjuvant CRT may help us to identify new or more appropriate targets for systemic therapy...
  43. ncbi Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    J Hematother Stem Cell Res 11:659-68. 2002
    ....
  44. ncbi Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy
    Benjamin F Johnson
    Duke University Medical Center, Duke University School of Medicine, Department of Medicine, Program in Molecular Therapeutics, Comprehensive Cancer Center, Box 2606, Durham, NC 27710, USA
    Expert Opin Biol Ther 7:449-60. 2007
    ..Several strategies tested so far have yielded incomplete, yet promising, results...
  45. ncbi HER2 dendritic cell vaccines
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Breast Cancer 3:S164-72. 2003
    ..The magnitude of the immune responses generated is fairly modest, and more potent DC loading and maturation strategies will be necessary to optimize these vaccines...
  46. ncbi Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine
    Takuya Osada
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Clin Cancer Res 15:2789-96. 2009
    ....
  47. ncbi Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors
    Elizabeth Dugan
    Duke University Medical Center, Durham, NC, 27710, USA
    Anticancer Res 29:5149-53. 2009
    ..To determine the maximally tolerated dose (MTD), recommended phase II dose (RPTD) and toxicity profile of gemcitabine plus irinotecan combination...
  48. ncbi An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Clin Invest 120:3234-41. 2010
    ..These data suggest that VRP-based vectors can overcome the presence of neutralizing antibodies to break tolerance to self antigen and may be clinically useful for immunotherapy in the setting of tumor-induced immunosuppression...
  49. ncbi Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs
    Takuya Osada
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Int Immunol 17:1143-55. 2005
    ..Conversely, the use of NKT cells along with anti-Th2 cytokine-neutralizing antibodies or CD4-negative NKT cell subset could enhance the generation of antigen-specific CTLs for adoptive immunotherapy...
  50. ncbi Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs
    Zhenlin Hu
    Department of Mechanical Engineering and Materials Science, Duke University, Durham, NC 27708, USA
    Biochem Biophys Res Commun 335:124-31. 2005
    ..The potency in APC activation produced by mechanical lysis is much stronger than thermal necrosis of the tumor cells. These findings suggest that optimization of treatment strategy may help to enhance HIFU-elicited anti-tumor immunity...
  51. ncbi Proteomics for monitoring immune responses to cancer vaccines
    Paul J Mosca
    Department of Surgery, Duke University Medical Center, Box 2606 DUMC, Durtham, NC 27710, USA
    Curr Opin Mol Ther 5:39-43. 2003
    ..Advances in miniaturization and automation may also permit characterization of the immune response more rapidly and from smaller amounts of biological material than is possible with existing assay systems...
  52. ncbi Depletion of human regulatory T cells
    Amy C Hobeika
    Departments of Surgery, Duke University Medical Center, Durham, NC, USA
    Methods Mol Biol 707:219-31. 2011
    ....
  53. ncbi Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations
    Takuya Osada
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27705, USA
    Cancer Res 71:4172-82. 2011
    ..Our findings support clinical explorations to reposition niclosamide for the treatment of CRC...
  54. ncbi Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines
    Timothy M Clay
    Duke Comprehensive Cancer Center, Department of Surgery, Duke University Medical Center, 2424 Erwin Road, Suite 601, Durham, NC 27710, USA
    Immunol Res 49:235-47. 2011
    ..Further, we will discuss new strategies to augment the clinical efficacy of cancer vaccines by enhancing vaccine immunogenicity and reversing the immunosuppressive tumor microenvironment...
  55. ncbi HER2 overexpression elicits a proinflammatory IL-6 autocrine signaling loop that is critical for tumorigenesis
    Zachary C Hartman
    Duke Comprehensive Cancer Center, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 71:4380-91. 2011
    ..We suggest that the HER2-IL-6-STAT3 signaling axis we have defined in breast cancer could prompt new therapeutic or prevention strategies for treatment of HER2-amplified cancers...
  56. ncbi Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand
    Paul J Mosca
    Department of General and Thoracic Surgery, Pathology, Immunology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Leukoc Biol 72:546-53. 2002
    ..The ability to generate phenotypically mature, IL-12-producing DC1 from peripheral blood mononuclear cells mobilized by Flt3L will have important implications for the development of effective cancer immunotherapy strategies...
  57. ncbi Recent clinical progress in virus-based therapies for cancer
    Christopher Y Woo
    Duke University Medical Center, Department of Medicine, Programme in Molecular Therapeutics, Comprehensive Cancer Center, 401 MSRB, Research Drive, Durham, NC 27710, USA
    Expert Opin Biol Ther 6:1123-34. 2006
    ..This review highlights the principles underlying virus-based therapies for cancer, with an emphasis on recent developments from the clinic...
  58. ncbi A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer
    Nan Soon Wong
    Duke University Medical Center, Durham, North Carolina, USA
    Cancer Invest 29:617-25. 2011
    ..Two patients had partial response; seven patients had stable disease at least 6 months. Oral lonafarnib at 150 mg a.m./100 mg p.m. plus gemcitabine at 1,000 mg/m(2) is the maximum tolerated dose with acceptable safety and tolerability...
  59. ncbi Immune monitoring
    Paul J Mosca
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Treat Res 123:369-88. 2005
    ..It should be the goal and expectation that this rational approach to immune monitoring will allow the critical appraisal of the most promising vaccine candidates in the context of pivotal, multi-center trials...
  60. ncbi Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients
    Michael A Morse
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 17:4844-53. 2011
    ..We wished to test whether targeted delivery of an otherwise poorly immunogenic, soluble antigen to APC through their mannose receptors (MR) would induce clinically relevant immunity...
  61. ncbi Assessing the quality of colorectal cancer care: do we have appropriate quality measures? (A systematic review of literature)
    Meenal Patwardhan
    Department of Medicine, Duke University Medical Center, Durham, NC, USA
    J Eval Clin Pract 13:831-45. 2007
    ..We also evaluated the extent to which these measures are ready to be implemented in clinical practice, and identified areas for future research...
  62. ncbi A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon
    Brian G Czito
    Department ofRadiation Oncology, Duke University Medical Center, Durham, NC, USA
    Int J Radiat Oncol Biol Phys 58:779-85. 2004
    ..One patient had a pathologic complete response. CONCLUSION: Preoperative chemoradiotherapy with oral eniluracil and 5-FU is feasible and well tolerated. Additional investigation is warranted...
  63. ncbi Gene therapy for lung cancer
    Eric M Toloza
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Cell Biochem 99:1-22. 2006
    ..This article will discuss the therapeutic implications of these molecular changes associated with bronchogenic carcinomas and will then review the status of gene therapies for treatment of lung cancer...
  64. ncbi Current status of dendritic cell immunotherapy of malignancies
    Paul J Mosca
    Departments of Surgery and Medicine, Duke University Medical Center, Durham, North Carolina, USA
    Int Rev Immunol 22:255-81. 2003
    ..Clinical responses such as stability of disease and tumor regressions have been reported in some patients, particularly with melanoma, myeloma, and prostate cancer...
  65. ncbi Recent areas of development for dendritic cell vaccines
    Michael A Morse
    Duke University Medical Center, Durham, NC 27710, USA
    Cancer Chemother Biol Response Modif 21:339-50. 2003
  66. ncbi Immunotherapeutic targeting of Wilms' tumor protein
    Yalonda Hutchings
    Duke University Medical Center, Departments of Medicine and Surgery, 401 MSRB, Research Drive, Durham, NC 27710, USA
    Curr Opin Mol Ther 9:62-9. 2007
    ..Because peptide-based vaccines are human leukocyte antigen-restricted, other more broadly applicable strategies are now being developed to activate WT1-specific immune responses, including the use of WT1-specific viral vectors...
  67. ncbi Immunoregulatory T cells in cancer immunotherapy
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Box 3233, Durham, NC 27710, USA
    Expert Opin Biol Ther 2:827-34. 2002
    ..One hypothesis is that depleting these CD4+CD25+ counter-regulatory T cells in humans with cancer will enhance the efficacy of anticancer immunisations...
  68. ncbi Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression
    Katherine M Aird
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Mol Cancer Ther 7:38-47. 2008
    ..These data have identified a novel functional link between ErbB2 signaling and antiapoptotic pathway mediated by XIAP. Blockade of the IAP antiapoptotic pathway alone or in combination would be an attractive strategy in IBC therapy...
  69. ncbi CEA loaded dendritic cell vaccines
    Michael A Morse
    Departments of Medicine and Surgery, Duke University Medical Center, P.O. Box 3233, Durham, NC 27710, USA
    Cancer Chemother Biol Response Modif 20:385-90. 2002
  70. ncbi Combining cancer vaccines with chemotherapy
    Gabriel Chong
    Division of Medical Oncology, Duke South Clinics, Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Pharmacother 6:2813-20. 2005
    ..As such, more preclinical and clinical trials are needed to explore the synergistic effects of chemotherapy combined with immunotherapy, particularly the proper dose and timing of chemotherapy...
  71. ncbi Dendritic cell vaccines
    Paul J Mosca
    Duke Comprehensive Cancer Center Duke University Medical Center, Durham, NC 27710, USA
    Front Biosci 12:4050-60. 2007
    ..The emphasis of dendritic cell immunotherapy research is increasingly shifting toward the development of strategies to increase the potency of dendritic cell vaccine preparations...
  72. ncbi DNA and RNA modified dendritic cell vaccines
    Michael A Morse
    Department of Medicine, Duke University Medical Center, Box 2606, Durham, North Carolina 27710, USA
    World J Surg 26:819-25. 2002
    ..Genetic modification can be effected by either DNA or RNA, and the genetic material may be delivered by vectors or by physical means. These approaches are now entering human clinical trials...
  73. ncbi Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review
    Robert G Prosnitz
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 107:2352-60. 2006
    ..Therefore, the authors conducted a systematic review of the literature to determine the available QMs for adjuvant CT and RT in patients with CRC and rated their usefulness for assessing the delivery of quality care...
  74. ncbi Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center
    Nicole L Hansen
    Department of Pharmacy, Duke University Medical Center, Durham, NC 27710, USA
    J Oncol Pharm Pract 17:125-30. 2011
    ....
  75. ncbi Current status of adoptive immunotherapy of malignancies
    Michael A Morse
    Department of Medicine and Surgery, Duke University Medical Center, MSRB Room 401, Box 3233, Durham, NC 27710, USA
    Expert Opin Biol Ther 2:237-47. 2002
    ..In addition to work being done to develop the most potent effector, other studies are working on improving T-cell trafficking to tumours and interfering with the tumour-induced immunosuppression that can impair in vivo T-cell activity...
  76. ncbi CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer
    Michael A Morse
    Duke University Medical Center, 10 Bryan Searle Drive, 477 Seeley G Mudd Building, Durham, NC 27710, USA
    Expert Rev Vaccines 10:733-42. 2011
    ..An ongoing Phase II trial evaluates CDX-1307 in patients with newly diagnosed, resectable, hCG-?-expressing bladder cancer, where low tumor burden and early intervention may provide greater potential for benefit...
  77. ncbi Cryosurgery after chemoembolization for hepatocellular carcinoma in patients with cirrhosis
    Pierre Alain Clavien
    Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Duke University Medical Center, Durham, NC, USA
    J Gastrointest Surg 6:95-101. 2002
    ..TACE may reduce the risk of hemorrhage after cryosurgery but can increase the risk of hepatic failure in patients with poor hepatic function...
  78. ncbi Pharmacological inhibition of TGF? as a strategy to augment the antitumor immune response
    Brent A Hanks
    Department of Internal Medicine, Division of Hematology and Oncology, Duke University Medical Center, 450 Research Drive, Durham, NC 27708, USA
    Curr Opin Investig Drugs 11:1342-53. 2010
    ....
  79. ncbi A year of successful cancer vaccines points to a path forward
    Michael A Morse
    Duke University Medical Center, Durham, NC 27710, USA
    Curr Opin Mol Ther 12:11-3. 2010
    ..These data support the further development of such vaccines, and provide guidance for the development of improved agents and protocols for the use of therapeutic vaccination to treat cancer...
  80. ncbi Dendritic cell maturation in active immunotherapy strategies
    Michael A Morse
    Department of Mecine and Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Expert Opin Biol Ther 2:35-43. 2002
    ....
  81. ncbi Adenovirus vaccine immunotherapy targeting WT1-expressing tumors
    Jeffrey M Clarke
    Department of Medicine, Duke University Medical Center, DUMC Box 31379, Durham, NC 27710, USA
    Expert Opin Biol Ther 10:875-83. 2010
    ..Wilm's Tumor gene (WT1) is a robust TAA which is overexpressed in many malignancies and has been recently used to develop a novel recombinant adenovirus (Ad-WT1) for antitumor immunotherapy...
  82. ncbi CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy
    Yanal M Murad
    Duke University Medical Center, Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, Durham, NC 27710, USA
    Expert Opin Biol Ther 7:1257-66. 2007
    ..Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer...
  83. ncbi Successful desensitization to oxaliplatin
    Lydia Mis
    Department of Pharmacy, Duke University Medical Center, Durham, NC 27710 3089, USA
    Ann Pharmacother 39:966-9. 2005
    ..To report the successful desensitization of a patient to oxaliplatin utilizing an 8-hour desensitization regimen in a controlled environment...
  84. ncbi Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Ann Surg Oncol 14:3481-91. 2007
    ..This multi-institutional retrospective study compared postoperative outcomes after simultaneous and staged colorectal and hepatic resections...
  85. ncbi Resection of noncolorectal nonneuroendocrine liver metastases: a comparative analysis
    Srinevas K Reddy
    Department of Surgery, Duke University Medical Center, Durham, NC 27713, USA
    J Am Coll Surg 204:372-82. 2007
    ..Although established for metastatic colorectal (CR) and neuroendocrine (NE) malignancies, the role of partial hepatectomy in management of metastases from other primaries (NCRNE) is not well-defined...
  86. ncbi Role of natural killer cell function in dendritic cell-based vaccines
    Christopher Y Woo
    Program in Molecular Therapeutics, Comprehensive Cancer Center, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Expert Rev Vaccines 5:55-65. 2006
    ..In this article, the authors will review studies focusing on NK-DC interactions and highlight the most recent clinical findings relating to the potential role of NK cells in DC-based vaccine therapy...
  87. ncbi De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant
    Michael A Heneghan
    Division of Gastroenterology, Duke University Medical Center, Durham, NC, USA
    Am J Transplant 3:634-8. 2003
    ..No viable tumor was identified in the explanted liver. This case establishes that long-term complications associated with PSC and biliary-enteric surgery such as CCA may become apparent in new grafts post-transplant...
  88. ncbi Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes
    Timothy M Clay
    Duke University Medical Center, Program in Molecular Therapeutics, Department of Surgery, Durham NC 27710, USA
    Expert Opin Biol Ther 2:353-60. 2002
    ....
  89. ncbi Technology evaluation: Rexin-G, Epeius Biotechnologies
    Michael Morse
    Duke University Medical Center, Division of Medical Oncology, Box 3233 Room 3803, Red Zone, Duke South Clinics, Durham, NC 27710, USA
    Curr Opin Mol Ther 7:164-9. 2005
    ..The therapy is currently undergoing phase I/II clinical trials...
  90. ncbi A phase II study of active immunotherapy with PANVAC or autologous, cultured dendritic cells infected with PANVAC after complete resection of hepatic metastases of colorectal carcinoma
    Emil Lou
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Clin Colorectal Cancer 5:368-71. 2006
  91. ncbi Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy
    Pierre-Alain Clavien
    Department of Surgery, Division of Hematology and Oncology, Duke University Medical Center, Durham, NC, USA
    Surgery 131:433-42. 2002
    ..This strategy appears particularly promising in patients with large HCC. This approach should be investigated further...
  92. ncbi Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells
    Smita K Nair
    Center for Genetic and Cellular Therapies, Duke University Medical Center, Durham, North Carolina 27710, USA
    Ann Surg 235:540-9. 2002
    ..CONCLUSIONS: DCs transfected with total tumor RNA may represent a method for inducing immune responses against the entire repertoire of tumor antigens of surgically resected malignancies...
  93. ncbi Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA
    Carlos Micames
    Duke University Medical Center, Department of Medicine, Durham, North Carolina 27710, USA
    Gastrointest Endosc 58:690-5. 2003
    ..A concern for peritoneal seeding of pancreatic cancer via percutaneous FNA is warranted. EUS-guided FNA is recommended as the method of choice for diagnosis in patients with potentially resectable pancreatic cancer...
  94. ncbi Adjuvant hepatic arterial chemotherapy following metastasectomy in patients with isolated liver metastases
    Mark Onaitis
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Ann Surg 237:782-8; discussion 788-9. 2003
    ..This fact, in light of the potential toxicity, would argue for a larger confirmatory trial of HAI in the adjuvant setting, incorporating recent advances in systemic therapy and careful attention to hepatotoxicity...
  95. ncbi Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression
    Benjamin Johnson
    Duke University Medical Center, MSRB Room 433, Box 3233, Durham, NC 27710, USA
    Curr Mol Med 9:702-7. 2009
    ..Therapies intended to inhibit VEGF or VEGF receptors have demonstrated improved anti-tumor immunity and enhanced responses to cancer vaccines...
  96. ncbi Update on anti-CTLA-4 antibodies in clinical trials
    Lee F Langer
    Duke University Medical Center, Department of Surgery, Program in Molecular Therapeutics, Comprehensive Cancer Center, Durham, NC 27710, USA
    Expert Opin Biol Ther 7:1245-56. 2007
    ..This article reviews preclinical development and data generated from Phase I, II and III studies with regard to the end points reported and immune-related adverse events...
  97. ncbi The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors
    Peter E Fecci
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 64:161-76. 2003
    ..The future success of clinical trials will depend on the optimization and standardizing of procedures for DC generation, loading, and administration...
  98. ncbi Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides
    Holden T Maecker
    BD Biosciences, San Jose, CA, USA
    BMC Immunol 9:9. 2008
    ..Here we assess the levels of intra-assay, inter-assay, and inter-operator precision, as well as linearity, of CD8+ T cell IFNgamma-based ELISPOT and cytokine flow cytometry (CFC), as well as tetramer assays...
  99. ncbi Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT
    Holden T Maecker
    BD Biosciences, San Jose, USA
    BMC Immunol 6:17. 2005
    ..In this study, we compared the performance of these assays on leukapheresed PBMC shipped overnight in medium versus cryopreserved PBMC from matched donors...
  100. ncbi Toward protecting the safety of participants in clinical trials
    Robert M Califf
    Duke Clinical Research Institute, Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA
    Control Clin Trials 24:256-71. 2003
    ..DMC composition and functions should be standardized and regulations should be harmonized nationally and internationally. Finally, there should be a concerted effort to study the efficacy of various components of the system...
  101. ncbi A need for effective adjuvants
    Campbell J Bunce
    Curr Opin Mol Ther 5:8-9. 2003